8-K ·Filed Jul 8, 2026

AZTA

Azenta, Inc.
MIXED
Impact 5/10
Horizonweeks Processed2mo ago SEC0001628280-26-047591
8-K material event: Items 1.01, 2.01
Actionable Insight ◆ Mixed

The $35M vendor loan matures October 1, 2026. Monitor Thelema's ability to secure third-party refinancing — a default risk could turn this into a collection event. The divestiture simplifies Azenta's portfolio; with ~$400M in pro forma cash/securities, watch for M&A or share buyback announcements. Earnings impact is muted since B Medical was already classified as discontinued operations.

DirectionMixed
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
AZTA ▲ +42.35% at T+60d
NEUTRAL call ✓ call won +42.35% · α vs SPY +40.04% · entry $24.51 → $34.89
Entry anchored
Jul 8, 04:28 AM ET
via exchange tick
T+1d
+3.71%
call +3.71% · α +2.87%
$25.42
settled 3mo ago
T+5d
+3.79%
call +3.79% · α +2.93%
$25.44
settled 3mo ago
T+20d
+29.82%
call +29.82% · α +26.55%
$31.82
settled 8w ago
T+60d
+42.35%
call +42.35% · α +40.04%
$34.89
settled yesterday

Price Chart

Loading chart...

Executive Summary

Azenta completed the sale of B Medical Systems to Thelema for $63M total consideration, consisting of $28M cash received and a $35M vendor loan secured by a first-priority pledge over B Medical's equity. The vendor loan carries 6.0% interest, matures in three months (October 1, 2026), and is classified as a related-party transaction since Thelema is majority-owned by Luc Provost, a VP of Azenta. The divestiture aligns with Azenta's strategy to focus on core life sciences, but the large vendor loan receivable ($35M) creates near-term credit risk and tied-up capital.

Key Financial Metrics

Deal Value
$63.0M
Deal Type
acquisition

Key Facts

  • Sale of B Medical Systems completed July 1, 2026 for fixed $63M total consideration.
  • $28M cash received ($9M deposit from Dec 2025 + $19M at closing); $35M funded via secured vendor loan at 6.0% p.a., maturing in 3 months.
  • Thelema, the buyer, is majority-owned by Luc Provost (Azenta VP and CEO of B Medical); Audit Committee approved the related-party transaction.
  • Pro forma balance sheet shows cash increases by ~$19M to $253M, a $35M short-term note receivable, and a $41.5M reduction in retained earnings (cumulative translation + costs to sell).
  • B Medical was already classified as a discontinued operation; the 8-K confirms no adjustment to previously estimated loss on disposal.

Financial Impact

Azenta receives $28M net cash proceeds and holds a $35M secured 3-month vendor loan. Retained earnings reduced by ~$41.5M (cumulative translation of $46.9M offset by $5.4M estimated cost to sell). Pro forma cash and marketable securities total ~$399.5M.

cashretained_earningsnote_receivableassets_disposed

Risk Factors

  • Thelema may fail to refinance the $35M vendor loan by October 1, 2026, creating a default and potential asset impairment or enforcement action.
  • Related-party nature (buyer owned by Azenta VP) increases governance scrutiny and potential reputational risk.
  • Cash position appears strong post-deal, but Azenta has not announced specific capital allocation plans — no buyback or M&A guidance provided.

Market Snapshot

Exchange
Nasdaq
Sector
Special Industry Machinery, NEC
Analyst Consensus
69% bullish (13 analysts)

Investment Themes

Industrials & Manufacturing

Documents Analyzed

This report is based on 9 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-047591
Exhibit: exhibit102-xexxazentaxthel.htm0001628280-26-047591
Exhibit: exhibit992-xunauditedprofo.htm0001628280-26-047591
Exhibit: exhibit22-xexxazentaxthele.htm0001628280-26-047591
Exhibit: exhibit991-xazentapressrel.htm0001628280-26-047591
Document: azta-20260701.htm0001628280-26-047591
Document: 0001628280-26-047591-index-headers.html0001628280-26-047591
Document: 0001628280-26-047591-index.html0001628280-26-047591
Document: 0001628280-26-047591.txt0001628280-26-047591
7 reports for AZTA
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for AZTA — sortable, filterable
TypeNow
Sep 4, 2026
28d ago
8-K
NEUTRAL ★ 4/10
$31.33 $32.04▲ +2.27%▲ +3.48%$38.75 (+23.68%)
Aug 24, 2026
5w ago
8-K
NEUTRAL ★ 4/10
$32.88 $32.65▼ −0.70%▼ −1.17%$38.75 (+17.85%)
Aug 8, 2026
7w ago
Institutional Cluster
MIXED ★ 5/10
$33.33 $33.58▲ +0.75%▲ +0.80%$38.75 (+16.26%)
Aug 4, 2026
8w ago
Press Release
BULLISH ★ 7/10
$31.82 $33.53▲ +5.37%▲ +5.02%$38.75 (+21.78%)
Jul 8, 2026
12w ago
8-K
MIXED ★ 5/10
$24.51 $25.44▲ +3.79%▲ +2.93%$38.75 (+58.10%)
May 5, 2026
21w ago
8-K
BEARISH ★ 8/10
$18.38 $17.53▲ +4.62%▲ +5.76%$38.75 (−110.83%)
Apr 7, 2026
25w ago
8-K
NEUTRAL ★ 6/10
$21.71 $24.26▲ +11.75%▲ +6.42%$38.75 (+78.49%)
Showing 7 of 7

US Market Status

Market Closed — Opens Mon (38h 33m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access